Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016; New Report Launched
Varicella Zoster (HHV-3) Infections pipeline therapeutics constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by Companies and remaining by the Universities/Institutes. Global Markets Direct's latest report Varicella Zoster (HHV-3) Infections – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Varicella Zoster (HHV-3) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
View full press release